News
BNTC
8.95
+0.92%
0.08
SUVRETTA CAPITAL MANAGEMENT LLC REPORTS A STAKE OF 19.99% IN BENITEC BIOPHARMA AS OF APRIL 22, 2024
Reuters · 6d ago
Benitec Biopharma 13G Filing Shows Steven Oliveira Reported A 8.89% Passive Stake In The Co As Of April 22
Benzinga · 6d ago
STEVEN OLIVEIRA REPORTS 8.89% PASSIVE STAKE IN BENITEC BIOPHARMA INC AS OF APRIL 22 - SEC FILING
Reuters · 6d ago
Weekly Report: what happened at BNTC last week (0422-0426)?
Weekly Report · 6d ago
Benitec Biopharma Price Target Raised to $16.00/Share From $10.00 by JMP Securities
Dow Jones · 04/22 16:28
Benitec Biopharma Is Maintained at Market Outperform by JMP Securities
Dow Jones · 04/22 16:28
JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $16
Benzinga · 04/22 16:17
Weekly Report: what happened at BNTC last week (0415-0419)?
Weekly Report · 04/22 12:08
Buy Rating Affirmed for Benitec Biopharma Following Promising BB-301 Trial Results and Financial Boost
TipRanks · 04/22 04:35
Benitec Biopharma’s $40 Million Equity Financing Deal
TipRanks · 04/19 10:13
12 Health Care Stocks Moving In Thursday's After-Market Session
Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. Biora Therapeutics, Mustang Bio and China SXT Pharmaceuticals were among the top gainers. Virpax Pharmaceuticals stock decreased by 18.2% during the session.
Benzinga · 04/18 20:31
Health Care Sector Update for 04/18/2024: TGTX, ME, ELV, BNTC
NASDAQ · 04/18 19:53
Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?
Benitec Biopharma released interim clinical data from the 90-day timepoint following the administration of BB-301 in Oculopharyngeal Muscular Dystrophy. OPMD is a rare progressive muscle-wasting disease. No severe side effects have been noted in the study.
Benzinga · 04/18 17:04
CGC, GENE and HOLO among mid-day movers
Seeking Alpha · 04/18 16:42
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 67.1% to $5.42 during Thursday's regular session. Aileron Therapeutics (NASdaq:ALRN) and 23andMe Holding moved upwards. Losers SeaStar Medical Holding and Aptorum Gr stock decreased by 27.0% during the session.
Benzinga · 04/18 16:31
Benitec Biopharma Showcases Encouraging Clinical Trial Results
TipRanks · 04/18 13:02
Benitec Biopharma reports positive data in early study for OPMD treatment
Seeking Alpha · 04/18 12:55
Market-Moving News for April 18th
Bio-Path Holdings shares are trading higher. Benitec Biopharma shares are also trading higher after announcing a $40 million financing. TH International reports a year-over-year increase in Q4 financial results. BP1002 is in a clinical trial to treat acute myeloid leukemia patients.
Benzinga · 04/18 12:35
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. 23andMe Holding stock moved upwards by 26.61% in the pre- market session. NRX Pharmaceuticals shares declined by 22.5% during the session.
Benzinga · 04/18 12:09
BENITEC BIOPHARMA INC: REGARDING BB-301 SAFETY PROFILE OBSERVED TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN OBSERVED FOR TWO SUBJECTS
Reuters · 04/18 11:30
More
Webull provides a variety of real-time BNTC stock news. You can receive the latest news about Benitec Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About BNTC
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).